Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors

  • ACS Med Chem Lett. 2019 Oct 22;10(11):1549-1553. doi: 10.1021/acsmedchemlett.9b00381.
Dries J H De Clercq  1  2 ,  David E Heppner  1  2 ,  Ciric To  3  4  5 ,  Jaebong Jang  1  2 ,  Eunyoung Park  1  2 ,  Cai-Hong Yun  1  2  6 ,  Mierzhati Mushajiang  3 ,  Bo Hee Shin  3 ,  Thomas W Gero  1  2 ,  David A Scott  1  2 ,  Pasi A Jänne  3  4  5  7 ,  Michael J Eck  1  2 ,  Nathanael S Gray  1  2
Affiliations
  • 1. Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
  • 2. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, United States.
  • 3. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
  • 4. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
  • 5. Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, United States.
  • 6. Department of Biochemistry and Biophysics, Peking University Health Science Center, Beijing 100191, China.
  • 7. Belfer Center for Applied Cancer Science, Boston, Massachusetts 02215, United States.
PMID: 31749909 DOI: 10.1021/acsmedchemlett.9b00381
Abstract

Allosteric kinase inhibitors represent a promising new therapeutic strategy for targeting kinases harboring oncogenic driver mutations in cancers. Here, we report the discovery, optimization, and structural characterization of allosteric mutant-selective EGFR inhibitors comprising a 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one scaffold. Our structure-based medicinal chemistry effort yielded an inhibitor (3) of the EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) mutants with an IC50 of ∼10 nM and high selectivity, as assessed by kinome profiling. Further efforts to develop allosteric dibenzodiazepinone inhibitors may serve as the basis for new therapeutic options for targeting drug-resistant EGFR mutations.

Products